Page last updated: 2024-08-05 11:02:06

indolocarbazole

Compounds based upon an indolo[2,3-a]carbazole skeleton.

ChEBI ID: 51915

Members (10)

MemberDefinitionRole
5,11-dihydroindolo[3,2-b]carbazole-12-carboxaldehyde5,11-dihydroindolo[3,2-b]carbazole-12-carboxaldehyde
arcyriaflavin aLSM-3627
go 6976Goe 6976
kt 5720An organic heterooctacyclic compound that is 1H,1'H-2,2'-biindole in which the nitrogens have undergone formal oxidative coupling to positions 2 and 5 of hexyl (3S)-3-hydroxy-2-methyltetrahydrofuran-3-carboxylate (the 2R,3S,5S product), and in which the 3 and 3' positions of the biindole moiety have also undergone formal oxidative coupling to positions 3 and 4 of 1,5-dihydro-2H-pyrrol-2-one.KT 5720
kt 5823An organic heterooctacyclic compound that is 1H,1'H-2,2'-biindole in which the nitrogens have undergone formal oxidative coupling to positions 2 and 5 of methyl (3R)-3-methoxy-2-methyltetrahydrofuran-3-carboxylate (the 2S,3R,5R product), and in which the 3 and 3' positions of the biindole moiety have also undergone formal oxidative coupling to positions 3 and 4 of 1-methyl-1,5-dihydro-2H-pyrrol-2-one.KT 5823
kt 5926An organic heterooctacyclic compound that is 5-propoxy-1H,1'H-2,2'-biindole in which the nitrogens have undergone formal oxidative coupling to positions 2 and 5 of methyl (3R)-3-hydroxy-2-methyltetrahydrofuran-3-carboxylate (the 2S,3R,5R product), and in which the 3 and 3' positions of the biindole moiety have also undergone formal oxidative coupling to positions 3 and 4 of 1,5-dihydro-2H-pyrrol-2-one.KT 5926
lestaurtinibLSM-1231
midostaurinAn organic heterooctacyclic compound that is the N-benzoyl derivative of staurosporine.midostaurin
rebeccamycinAn N-glycosyl compound consisting of a heteropolycyclic ring system with a glucosyl group attached to one of the indolic nitrogens.rebeccamycin
sb 218078LSM-1274

Research

Studies (1,871)

TimeframeStudies, Drugs in This Class (%)All Drugs %
pre-19903 (0.16)18.7374
1990's345 (18.44)18.2507
2000's848 (45.32)29.6817
2010's541 (28.92)24.3611
2020's134 (7.16)2.80

Study Types

Publication TypeStudies, Drugs in This Class (%)All Drugs (%)
Trials55 (2.73%)5.53%
Reviews118 (5.86%)6.00%
Case Studies32 (1.59%)4.05%
Observational2 (0.10%)0.25%
Other1,806 (89.72%)84.16%